Abstract: The present invention relates to peptides, referred to as CBD-1, CBD-2, CBM-1/TH-1, CBM-1/TH-2, CBM-2/TH-1, CBM-2/TH-2 and C-20 peptides, which are antigenic and elicit a protective immune response against HIV infection. Compositions, pharmaceutical compositions and vaccines comprising these antigenic peptides are also encompassed by the present invention, as well as neutralizing antibodies which inhibit infection of primary CD4+ T lymphocytes by various HIV isolates. Methods for diagnosis of HIV are also disclosed.
Type:
Grant
Filed:
March 11, 2008
Date of Patent:
May 8, 2012
Assignees:
Institut Pasteur, Centre National de la Recherche Scientifique
Inventors:
Ara Hovanessian, Jean-Paul Briand, Sylviane Muller, Bernard Krust, Josette Svab, Elias Said
Abstract: The present invention relates to peptides, referred to as CBD-1, CBD-2, CBM-1/TH-1, CBM-1/TH-2, CBM-2/TH-1, CBM-2/TH-2 and C-20 peptides, which are antigenic and elicit protective immune response against HIV infection. Compositions, pharmaceutical compositions and vaccines comprising these antigenic peptides are also encompassed by the present invention, as well as neutralizing antibodies which inhibit infection of primary CD4+ T lymphocytes by various HIV isolates. Methods for diagnosis of HIV are also disclosed.
Type:
Application
Filed:
March 11, 2008
Publication date:
September 30, 2010
Inventors:
Ara Hovanessian, Jean Paul Briand, Sylviane Muller, Bernard Krust, Josette Svab, Elias Said